Q2 2026 Strata Critical Medical Inc Earnings Call Transcript
Key Points
- Clinical revenue grew 15.1% sequentially on an organic basis, with transplant clinical revenue up 23.8%.
- Generated $5.7 million in operating cash flow and $2.9 million in free cash flow, marking the second consecutive quarter of cash generation.
- Completed three strategic bolt-on acquisitions at mid-single-digit multiples, expanding clinical footprint and adding over $20 million in revenue and $6.3 million in projected annualized adjusted EBITDA.
- Raised 2026 revenue guidance to $285-$295 million and adjusted EBITDA guidance to $33-$35 million, reflecting strong performance and acquisition contributions.
- NRP penetration rose to 59% of DCD donors, supporting continued growth in heart, liver, and lung transplants and benefiting the company's integrated services.
- Capital deployment plan is ahead of schedule, with a strong pipeline of additional opportunities and expected $17.5 million Joby performance earnout by year-end.
- Logistics revenue growth moderated to 6.9% year-over-year, with a sequential increase of only 1%, below expectations.
- A non-exclusive customer significantly reduced flying for one organ type, creating a 3% logistics revenue headwind expected to persist into Q3.
- Logistics gross margin fell to 18.4% in Q2, below the 20% target, due to higher fuel surcharges, unfavorable customer mix, and increased unscheduled maintenance costs.
- Q3 logistics revenue is expected to decline high single-digits sequentially due to the customer headwind and typical summer seasonality.
- Free cash flow guidance remains at $15-$22 million, with higher non-recurring cash costs and working capital build offsetting increased adjusted EBITDA.
- The company expects a slower pace of acquisition activity in the second half of the year, potentially limiting near-term growth catalysts.
Good morning, ladies and gentlemen, and welcome to the Strata Critical Medical Fiscal Second Quarter 2026 Earnings Release Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time.
As a reminder, this call is being recorded. I would now like to turn the conference over to Matt Schneider, CFO of Clinical Services and Vice President of Finance and Investor Relations. Matt, you may begin.
Thank you for standing by, and welcome to Strata's conference call and webcast for the quarter ended June 30th, 2026. We appreciate everyone joining us today.
Before we get started, I would like to remind you of the company's forward-looking statement in safe harbor language. Statements made in this conference call that are not historical facts, including statements about future time periods, may be deemed to constitute forward-looking statements within the meaning of the Private
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
